Modulation of Cerebral Blood Flow Using Iron Chelators "DFO"

Completed

Phase 0 Results N/A

Trial Description

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Conditions

Interventions

  • Desferrioxamine Drug
    Other Names: Desferal, desferoxamine
    Intervention Desc: intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
    ARM 1: Kind: Experimental
    Label: Healthy young
    Description: Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
    ARM 2: Kind: Experimental
    Label: healthy old
    Description: Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Intervention: Crossover Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary Define change from baseline cerebral blood flow after receiving DFO infusion. baseline, 3hr, 6hr, 9hr No
Primary Determine if DFO changes blood HIF-1 levels from baseline and whether this correlates with changes in cerebrovascular hemodynamics. baseline, 3hr, 6hr, 9hr No

Sponsors